Latest News and Press Releases

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

New breakthrough data from studies with Coave’s ALIGATER™-engineered AAV2-based capsid coAAV-CSF-01 (S01coAAV2) demonstrates improved brain tissue transduction and safety following intra-cerebrospinal...

Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Highly experienced in gene therapy dealmaking, Pettenaro will be driving Coave’s business development activities and establish its presence in the Boston biotech hub  Paris, France, and Cambridge,...

Paris, France, April 9, 2025 – Coave Therapeutics (‘Coave’), a company pioneering the future of genetic medicines, announces that members of its leadership team will be attending the following...

AAVantgarde announces 2 presentations at ARVO 2025 annual meeting

Copenhagen, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Gene therapy's biggest obstacle isn't science - it's manufacturing. While the field races forward with breakthrough treatments, production remains stuck...

GUANGZHOU, China, Feb. 25, 2025 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading Urban Air Mobility (“UAM”) technology platform company,...

GUANGZHOU, China, Jan. 21, 2025 (GLOBE NEWSWIRE) -- EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading Urban Air Mobility (“UAM”) technology platform company,...

Le tour de table a été mené par Novo Holdings A/S et Bpifrance (dans le cadre de la stratégie d'investissement InnoBio), avec la participation d'investisseurs américains et européens, Invus et UI...